Novavax Inc (NVAX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.41B
Last updated: Nov 17, 2026 at 11:06 AM ET
Novavax Inc (NVAX) Stock Forecast
Analysts expect Novavax (NVAX) to earn -$0.05 per share in the fiscal year ending Dec 31, 2026, on revenue of $473.10M. Of 9 analysts, 5 rate the stock Buy or Strong Buy, 1 Hold and 3 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 3 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 9 ratings average 3.00, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 56% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 5 | 55.6% |
| Hold | 1 | 11.1% |
| Sell | 1 | 11.1% |
| Strong Sell | 2 | 22.2% |
- Consensus
- Hold
- Total analysts
- 9
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates fall 48.0%.
- Fiscal year ending Dec 31, 2026
- -$0.05
- EPS consensus, revenue $473.10M
- Fiscal year ending Dec 31, 2027
- -$0.45
- EPS consensus, revenue $246.08M
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.05 | -$0.38 to $0.35 | 8 | $473.10M | $407.60M to $580.41M | 8 |
| Dec 31, 2027 | -$0.45 | -$1.35 to $0.35 | 8 | $246.08M | $160.00M to $338.98M | 8 |
Quarterly Estimates
The EPS consensus falls from $0.55 for the quarter ending Dec 31, 2026 to -$0.35 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.55 | $0.18 to $0.98 | 10 | $222.64M | $140.24M to $331.70M | 10 |
| Mar 31, 2027 | -$0.35 | -$0.45 to -$0.24 | 3 | $35.82M | $28.45M to $43.20M | 2 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 4 upward and 3 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 3 | 2 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.63.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.05 | -$0.52 | -$0.59 | -$0.63 | -$0.63 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.45 | -$0.13 | -$0.08 | -$0.22 | -$0.22 | N/A |
| Quarter ending Mar 31, 2027 | -$0.35 | -$0.32 | -$0.31 | -$0.31 | -$0.31 | N/A |
Frequently Asked Questions About NVAX
What is the NVAX stock forecast?
Consensus analyst estimates put Novavax's EPS at -$0.05 for the fiscal year ending Dec 31, 2026, on revenue of $473.10M. The consensus rating from 9 analysts is Hold.
How do analysts rate NVAX stock?
Of 9 analysts covering Novavax, 0 rate it Strong Buy, 5 Buy, 1 Hold, 1 Sell and 2 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from NVAX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.05, with estimates from -$0.38 to $0.35 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.45, with estimates from -$1.35 to $0.35 from 8 analysts.
What revenue do analysts expect from Novavax next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $473.10M, with estimates from $407.60M to $580.41M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $246.08M, with estimates from $160.00M to $338.98M.
How many analysts cover NVAX?
9 analysts rate Novavax stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
NVAX pages: Overview, Earnings, Forecast, Financials, Competitors